Breaking News

PMV Pharmaceuticals Announces Initial PC14586 Phase 1 Clinical Data to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

PMV Pharmaceuticals, Inc. Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract highlights 3/10 (30%) partial responses in patients treated in higher dose cohorts and activity observed in multiple tumor types Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented during oral presentation on June 7 Company […]